Zobrazeno 1 - 10
of 14
pro vyhledávání: '"William R, Spreen"'
Autor:
Parul Patel, Paula Teichner, Emilie Elliot, Marta Boffito, Milena Murray, Joseph W. Polli, Mark Baker, Susan L. Ford, Kelong Han, Alberto Russu, Herta Crauwels, Ronald D. D’Amico, William R. Spreen, Jean van Wyk
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 10 (2023)
Cabotegravir (CAB) and rilpivirine (RPV) is the first complete long-acting (LA) injectable regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression in people with HIV-1 who are virologically suppressed on a stabl
Externí odkaz:
https://doaj.org/article/6ced232122ea4106b728a36f74e12256
Autor:
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre-Marie Girard, Alexander Wong, Norma Porteiro, Susan Swindells, Jacques Reynes, Sebastian Noe, Conn Harrington, Carlos Martín Español, Carolina Acuipil, Asma Aksar, Yuanyuan Wang, Susan L Ford, Herta Crauwels, Veerle van Eygen, Rodica Van Solingen-Ristea, Christine L Latham, Shanker Thiagarajah, Ronald D’Amico, Kimberly Y Smith, Kati Vandermeulen, William R Spreen
Publikováno v:
Clinical Infectious Diseases. 76:1646-1654
Background Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic suppression. Here, we report the antiretroviral therapy as long acting su
Autor:
Parul Patel, Susan L. Ford, Mark Baker, Claudia Meyer, Louise Garside, Ronald D'Amico, Rodica Van Solingen‐Ristea, Herta Crauwels, Joseph W. Polli, Ciara Seal, Itziar Yagüe Muñoz, Shanker Thiagarajah, Eileen Birmingham, William R. Spreen, Bryan Baugh, Jean van Wyk, Vani Vannappagari
Publikováno v:
HIV Medicine. 24:568-579
Limited data exist on pregnant women living with HIV exposed to cabotegravir + rilpivirine (CAB + RPV). Outcomes in pregnant participants exposed to CAB + RPV, and pharmacokinetic washout data in those exposed to CAB + RPV long-acting (LA) with live
Autor:
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Parul Patel, Katy P. Moore, Ciara S. Seal, Amy G. Cutrell, Ronald D. D'Amico, Paul D. Benn, Raphael J. Landovitz, Mark A. Marzinke, William R. Spreen, Susan L. Ford
Publikováno v:
British journal of clinical pharmacology, vol 88, iss 10
AimTo characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies and evaluate the association of intrinsic and extrinsic factors with pharmacokinetic variability.MethodsAnalyses were implemented in NONMEM and R. Co
Autor:
Raphael J Landovitz, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y Liu, Manya Magnus, Mina C Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Paul Richardson, Mark A Marzinke, Craig W Hendrix, Susan H Eshleman, Yinfeng Zhang, Elizabeth Tolley, Jeremy Sugarman, Ryan Kofron, Adeola Adeyeye, David Burns, Alex R Rinehart, David Margolis, William R Spreen, Myron S Cohen, Marybeth McCauley, Joseph J Eron
Publikováno v:
PLoS Medicine, Vol 15, Iss 11, p e1002690 (2018)
BACKGROUND:Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspens
Externí odkaz:
https://doaj.org/article/830d37bc7c0d4f32b2594bc89a7448f5
Autor:
Cindy P, Garris, Maggie, Czarnogorski, Marybeth, Dalessandro, Ronald, D'Amico, Toyin, Nwafor, Will, Williams, Deanna, Merrill, YuanYuan, Wang, Larissa, Stassek, Michael B, Wohlfeiler, Gary I, Sinclair, Leandro A, Mena, Blair, Thedinger, Jason A, Flamm, Paul, Benson, William R, Spreen
Publikováno v:
Journal of the International AIDS Society. 25
The CUSTOMIZE hybrid III implementation-effectiveness study evaluated implementation of once-monthly long-acting (LA) cabotegravir + rilpivirine in diverse US healthcare settings. Here, we report patient participant perspectives after 12 months in CU
Autor:
Kelong Han, Paul Wannamaker, Hongzhou Lu, Biao Zhu, Meixia Wang, Melanie Paff, William R. Spreen, Susan L. Ford
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Long-acting (LA) cabotegravir demonstrated superior efficacy versus daily oral standard-of-care for HIV-1 preexposure prophylaxis. This phase 1 study assessed safety, tolerability, pharmacokinetics, and acceptability of cabotegravir in 47 HIV-negativ
Autor:
Maggie Czarnogorski, Cindy P. Garris, Marybeth Dalessandro, Ronald D'Amico, Toyin Nwafor, Will Williams, Deanna Merrill, YuanYuan Wang, Larissa Stassek, Michael B. Wohlfeiler, Gary I. Sinclair, Leandro A. Mena, Blair Thedinger, Jason A. Flamm, Paul Benson, William R. Spreen
Publikováno v:
Journal of the International AIDS Society. 25(9)
CUSTOMIZE evaluated the implementation of long-acting (LA) cabotegravir + rilpivirine, a novel healthcare provider-administered injectable antiretroviral therapy regimen, in diverse US healthcare settings. Findings from staff-study participants (SSPs
Autor:
Sinead Delany-Moretlwe, James P. Hughes, Peter Bock, Samuel Gurrion Ouma, Portia Hunidzarira, Dishiki Kalonji, Noel Kayange, Joseph Makhema, Patricia Mandima, Carrie Mathew, Elizabeth Spooner, Juliet Mpendo, Pamela Mukwekwerere, Nyaradzo M. Mgodi, Patricia Nahirya Ntege, Gonasagrie Nair, Clemensia Nakabiito, Harriet Nuwagaba-Biribonwoha, Ravindre Panchia, Nishanta Singh, Bekezela Siziba, Jennifer Farrior, Scott Rose, Rebecca Berhanu, Peter L Anderson, Yaw Agyei, Susan H. Eshleman, Mark A. Marzinke, Estelle Piwowar-Manning, Craig W. Hendrix, Aida Asmelash, Francesca Conradie, Michelle Moorhouse, Paul Richardson, Stephanie Beigel-Orme, Lynda Emel, Kevin Bokoch, Rhonda White, Sybil Hosek, Elizabeth Tolley, Nirupama Sista, Katherine Shin, Adeola Adeyeye, James Rooney, Alex R. Rinehart, William R Spreen, Kimberly Smith, Brett Hanscom, Myron S. Cohen, Mina C. Hosseinipour
Publikováno v:
SSRN Electronic Journal.
Autor:
Kenneth C Sutton, Jerome De Vente, Roger Leblanc, Edwin Dejesus, Graham Smith, Anthony Mills, Jean-Guy Baril, Marty St. Clair, Britt S Stancil, Kati Vandermeulen, William R Spreen
Publikováno v:
Open forum infectious diseases. 9(4)
Background In the LATTE study, daily oral cabotegravir + rilpivirine demonstrated higher rates of efficacy than efavirenz + 2 nucleoside reverse-transcriptase inhibitors (NRTIs) through Week 96 in antiretroviral therapy (ART)-naive adults with human